Recently, Pfizer Nematovir Tablets/Litonavir Tablets Combination Packaging (Paxlovid) failed to pass the 2022 National Medical Insurance Drug Catalog Negotiation, which caused widespread concern in the society. There were public concerns that this would affect the drug security of COVID-19. At the press conference held by the joint defense and control mechanism of the State Council on January 11, Huang Xinyu, Deputy Director of the Medical Service Management Department of the State Medical Insurance Bureau, responded to this. He said that some new drugs for COVID-19 treatment might be applied for listing in succession in the near future. With the increase of the number of new drugs on the market, patients' clinical medication selection, support ability and level will be further improved. At the meeting, civil affairs, postal services and other departments also introduced a number of measures to protect people's drug use for COVID-19 infection, in order to effectively meet drug demand. Paxlovid can still be temporarily reimbursed until March 31 this year. According to the introduction, in order to deal with the COVID-19, the medical insurance policy can temporarily include the treatment drugs of COVID-19 within the diagnosis and treatment plan of COVID-19 and outside the medical insurance directory into the medical insurance payment scope. With the update of the diagnosis and treatment plan, the National Health Insurance Bureau will adjust the scope of medical insurance payment. In recent years, in the adjustment of the medical insurance drug list, COVID-19 has always received high attention. It is reported that three types of COVID-19 treatment drugs were included in the negotiation scope of the 2022 medical insurance catalog, including Paxlovid, Azovudine Tablets, and Qingfei Paidu Granules. Among them, the negotiation of Azovudine Tablets and Qingfei Paidu Granules was successful, but Paxlovid failed due to the high quotation. "Don't worry too much. In the notice on optimizing the medical security policy for treatment expenses after the COVID-19 'Class B B management' just formulated by the National Health Insurance Bureau last week, the temporary payment policy for medical insurance for drugs out of the catalog within the diagnosis and treatment plan was clearly extended, and the payment was made first until March 31 this year." Huang Xinyu said that during this period, patients' medication would not be affected. "In our medical insurance catalogue, there are more than 600 symptomatic drugs for treating colds, fever, coughs and the like, and the insured people have a relatively rich clinical choice of drugs." Huang Xinyu introduced that the number of COVID-19 new drugs on the market will also further increase in the future, and the National Health Insurance Bureau will further strengthen the monitoring and management of COVID-19 drug prices, do a good job of COVID-19 treatment cost protection, and strive to reduce the economic burden of insured people. The express industry ensures the priority delivery of drugs, medical supplies and other medical supplies. In the near future, the demand for the delivery of drugs and other medical supplies is very urgent. The National Post Office has also made relevant arrangements for the delivery of related goods. Bian Zuodong, deputy director of the Market Supervision Department of the State Postal Administration, said that the postal express industry is mainly responsible for personal delivery and the delivery of medical materials such as drugs, N95 masks, antigen reagents purchased through the Internet. The State Post Office and the Ministry of Commerce jointly issued a notice detailing the relevant work requirements for continuously strengthening the dynamic monitoring of medical materials, taking various means to ensure the priority treatment of medical materials and express mail, and formulating effective measures to do a good job in the distribution of medical materials. The State Postal Administration further urged and guided the postal express enterprises to carry out special marking, key guarantee and priority delivery of medical material mail, and urged the enterprises to carry out dynamic tracking and special monitoring of the delivered medical material mail, and set up a special team to ensure medical materials